Guilty plea in UnitedHealthcare CEO killing comes amid sustained focus on obstacles to care

Luigi Mangione pleaded guilty Aug. 14 to federal stalking charges in the 2024 fatal shooting of UnitedHealthcare’s CEO, potentially bringing resolution to an incident that spurred introspection by insurers and the healthcare industry.

The charges, stemming from the killing of Brian Thompson on Dec. 4, 2024, carry a maximum penalty of life in prison. Prosecutors said they will seek that sentence at a hearing scheduled for Dec. 18.

The shooting generated widespread discussion and debate regarding the healthcare industry, with online reports and criticism emerging about coverage denials and delays.

Mangione, 28, said in remarks to the court that his experience navigating the healthcare system while dealing with a debilitating back injury drove him to target Thompson, according to a partial hearing transcript uploaded by Mangione’s defense team.

“He believed that the system had failed him and destroyed his life,” Mangione’s attorney, Karen Friedman Agnifilo, said in a statement to reporters.

Prosecutors have said there’s no indication that Mangione was ever enrolled in a UnitedHealthcare plan.

More on the plea and shooting

The shooting took place in midtown Manhattan as Thompson, 50, walked to an investor conference hosted by UnitedHealth Group, the parent company of UnitedHealthcare. Mangione said during the court hearing that he posed “as an investor at a firm managing over $50 billion in assets” when he contacted the company to find out the location of the conference.

He told the court he “understood my actions would place [Thompson] in fear of death and bodily injury.”

Thompson’s family, including his widow and two sons, said they supported the plea arrangement.

 “While nothing will ease the pain of losing him, we are grateful that the federal justice system has held the person responsible for this heinous act accountable,” the family wrote in a statement. “Now we look to the court to ensure that sentencing reflects the severity of this crime.”

Mangione also faces murder charges in New York state, with the trial set to get underway Sept. 8. His legal team is arguing those charges should be dismissed under double-jeopardy guidelines following Friday’s plea in the federal case.

(Update: On Aug. 17, Mangione’s state trial was delayed indefinitely to consider his defense team’s bid to have the charges dismissed.)

Tragedy put a spotlight on insurance processes

While stakeholders across healthcare took time after the shooting to consider ways to give patients a better experience, insurers carried the brunt of the repercussions. Polling and online chatter after the shooting suggested widespread resentment toward the health insurance sector.

In one survey conducted within two weeks of the shooting, nearly 80% blamed the incident on Mangione, but nearly 70% said the business practices of insurers also shouldered at least a moderate amount of responsibility. Younger respondents were less likely than others to blame Mangione, according to a report on the poll.

Along with claim denials and lack of available providers within insurance networks, survey responses indicated prior-authorization processes were an obstacle in the healthcare system.

In an initiative announced by CMS in June 2025, UnitedHealthcare and other major health insurers pledged to take several steps, among them reducing prior authorization volume, carrying over prior authorization decisions when patients switch health plans, expanding real-time approvals and improving transparency. In April 2026, the advocacy group AHIP said participating insurers had eliminated 11% of prior authorization volume, amounting to 6.5 million requests.

At the 2025 announcement, Mehmet Oz, MD, administrator of CMS, was asked why he thought insurers would hold to their assurances. “There’s violence in the streets over these issues,” he responded, in part.

On its end, UnitedHealthcare has committed to reduce prior authorization volume by 30% before the end of 2026. Affected services include outpatient surgeries and certain outpatient therapies, chiropractic care, and certain diagnostic tests. For pediatric services, two-thirds of prior authorization requirements are due to be eliminated.

UnitedHealthcare also plans to move more than 70% of prior authorization volume into an industrywide standardized electronic submission process by year’s end, according to a separate announcement.

Data reflect notable prior authorization denial rates

New data from KFF show that in 2025, insurers denied 12% of prior authorization standard (non-expedited) requests in Medicare Advantage (MA), 14% in Medicaid and 18% in the Affordable Care Act marketplaces. Denials of expedited requests were 2 percentage points lower in each segment.

In MA, UnitedHealthcare denied 17% of non-expedited requests, the most of any insurer. Independence Health had the most such denials in Medicaid (23%), while Centene (25%) topped the list in the marketplaces.

Prior authorization denials were overturned in 67% of cases in MA, 47% in Medicaid and 43% in the marketplaces.

Progress was evident in turnaround times of prior authorization requests. Median response time for standard requests across insurance segments was roughly one day, and MA plans returned decisions in half a day for expedited requests. The lower times can be linked to the increasing prevalence of electronic prior authorization, according to the report.

Regarding transparency within prior authorization, the report states that “difficulty locating and interpreting metrics on insurer websites and gaps in how (e.g., a standardized template that insurers are required to use) and what metrics (e.g., denominators and breakouts by service category) must be reported limit the usability of this information directly by the public.”

Even if the apparent prior authorization improvements continue, provider advocates have argued that insurers are using other mechanisms to influence healthcare utilization and reimbursement. Examples are concurrent and retrospective review, formulary restrictions and site-based payment downgrades.